The Stanford Innovative Medicines Accelerator (IMA) is now accepting proposals for projects that address two key challenges in antibody and protein drug development: the identification of drug candidates and their optimization into clinical leads.
The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in small molecule drug discovery: adaptation of lab-grade assays to high- throughput screening (HTS) formats, and optimization of lead compounds into drug prototypes.
The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in drug development: identification of drug candidates and optimization towards clinical gene and cell therapy products.
The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for human subjects research that fosters the clinical development of new or existing drugs, vaccines, and companion biomarkers that directly enable drug development.
The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in small molecule drug discovery: adaptation of lab-grade assays to high- throughput
screening (HTS) formats and optimization of lead compounds into drug prototypes.
Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug candidates and optimization towards clinical leads.
Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals for projects that use a recent advance in human organ modeling to address the IMA’s goals of accelerating the prototyping of innovative medicines and vaccines.
The Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes.
The Innovative Medicines Accelerator seeks to accelerate the prototyping of innovative early-stage translational stem cell and gene therapies that address unmet clinical needs.
The Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes.
